+

WO1998052590A3 - Improved delivery of disease modifiers - Google Patents

Improved delivery of disease modifiers Download PDF

Info

Publication number
WO1998052590A3
WO1998052590A3 PCT/CA1998/000448 CA9800448W WO9852590A3 WO 1998052590 A3 WO1998052590 A3 WO 1998052590A3 CA 9800448 W CA9800448 W CA 9800448W WO 9852590 A3 WO9852590 A3 WO 9852590A3
Authority
WO
WIPO (PCT)
Prior art keywords
improved delivery
disease modifiers
disease
hyaluronan
modifiers
Prior art date
Application number
PCT/CA1998/000448
Other languages
French (fr)
Other versions
WO1998052590A2 (en
Inventor
Eva Anne Turley
Original Assignee
Hyal Pharma Corp
Eva Anne Turley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharma Corp, Eva Anne Turley filed Critical Hyal Pharma Corp
Priority to AU73286/98A priority Critical patent/AU740631B2/en
Priority to JP54972998A priority patent/JP2001526666A/en
Priority to NZ501270A priority patent/NZ501270A/en
Priority to EP98920426A priority patent/EP0998297A2/en
Publication of WO1998052590A2 publication Critical patent/WO1998052590A2/en
Publication of WO1998052590A3 publication Critical patent/WO1998052590A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition component comprising hyaluronan binding motif (HBM) interposed between a form of hyaluronan having a molecular weight (protein standard) less than 750'000 daltons and a disease modifier which comprises a peptide or protein.
PCT/CA1998/000448 1997-05-22 1998-05-11 Improved delivery of disease modifiers WO1998052590A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU73286/98A AU740631B2 (en) 1997-05-22 1998-05-11 Improved delivery of disease modifiers
JP54972998A JP2001526666A (en) 1997-05-22 1998-05-11 Improved release of disease modulators
NZ501270A NZ501270A (en) 1997-05-22 1998-05-11 Pharmaceutical composition comprising hyaluronan (Mr less than 750,00) and a disease modifier (cytokine, a peptide mimicking a cytokine or a protein mimicking a cytokine) to enhance delivery of disease modifiers
EP98920426A EP0998297A2 (en) 1997-05-22 1998-05-11 Improved delivery of disease modifiers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002205771A CA2205771C (en) 1997-05-22 1997-05-22 Improved delivery of disease modifiers
CA2,205,771 1997-05-22

Publications (2)

Publication Number Publication Date
WO1998052590A2 WO1998052590A2 (en) 1998-11-26
WO1998052590A3 true WO1998052590A3 (en) 1999-04-22

Family

ID=4160694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1998/000448 WO1998052590A2 (en) 1997-05-22 1998-05-11 Improved delivery of disease modifiers

Country Status (6)

Country Link
EP (1) EP0998297A2 (en)
JP (1) JP2001526666A (en)
AU (1) AU740631B2 (en)
CA (1) CA2205771C (en)
NZ (1) NZ501270A (en)
WO (1) WO1998052590A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US20030082586A1 (en) 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
CA2406593A1 (en) * 2000-04-20 2001-11-01 Cangene Corporation Rhamm peptide conjugates
CA2524950A1 (en) * 2003-05-07 2004-12-02 La Jolla Institute For Molecular Medicine Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using high molecular weight hyaluronic acid
DE202011109558U1 (en) * 2011-12-09 2012-12-12 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Composition for topical use in inflammatory diseases of the skin and / or mucosa
FR3002452B1 (en) * 2013-02-28 2016-02-12 Dermaconcept Jmc TOPIC ANTIMICROBIAL DERMATOLOGICAL COMPOSITION
US10072075B2 (en) 2015-09-23 2018-09-11 Genentech, Inc. Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004058A2 (en) * 1989-09-21 1991-04-04 Norpharmco Inc. Treatment of conditions and disease
WO1993021312A1 (en) * 1992-04-09 1993-10-28 University Of Manitoba Hyaluronan receptor (rhamm = receptor for hyluronan mediated mobility) and hyaluronan binding peptides
WO1996006622A1 (en) * 1991-07-03 1996-03-07 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004058A2 (en) * 1989-09-21 1991-04-04 Norpharmco Inc. Treatment of conditions and disease
WO1996006622A1 (en) * 1991-07-03 1996-03-07 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
WO1993021312A1 (en) * 1992-04-09 1993-10-28 University Of Manitoba Hyaluronan receptor (rhamm = receptor for hyluronan mediated mobility) and hyaluronan binding peptides

Also Published As

Publication number Publication date
CA2205771A1 (en) 1998-11-22
AU7328698A (en) 1998-12-11
EP0998297A2 (en) 2000-05-10
AU740631B2 (en) 2001-11-08
WO1998052590A2 (en) 1998-11-26
CA2205771C (en) 2002-05-14
NZ501270A (en) 2001-08-31
JP2001526666A (en) 2001-12-18

Similar Documents

Publication Publication Date Title
EP1304346A3 (en) Conjugate of polyethylene glycol and chitosan
EP0809996A3 (en) Interferon conjugates
AU2075897A (en) Delivery system using mab 3e10 and mutants and/or functional fragments thereof
AU7678196A (en) Methods and compositions for the delivery of monomeric proteins
WO1993025583A3 (en) Proteinoid carriers and methods for preparation and use thereof
HUP9904174A3 (en) Pharmaceutical composition for transdermic delivery
WO1997038689A3 (en) Enteric-coated pharmaceutical compositions of mycophenolate
AU1180997A (en) Novel taxoids, their preparation and pharmaceutical compositions containing them
ZA975533B (en) Cyclosporin-containing pharmaceutical composition.
AU2137497A (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
HK1029124A1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them.
WO1999040112A8 (en) Neuroprotective peptides and uses thereof
AU4468197A (en) Hyaluronic drug delivery system
CA2263181A1 (en) Anti-chlamydial methods and materials
WO1998019697A3 (en) Novel pharmaceutical compositions
NZ305735A (en) Cyclic peptide antifungal agents, preparation and pharmaceutical compositions thereof
EP0950708A3 (en) Enhanced affinity hyaluronan binding peptides
AU6175398A (en) New delivery system for administering dentin-hypersensitivity-ameliorating compositions
WO1998052590A3 (en) Improved delivery of disease modifiers
AU2975899A (en) Colonic delivery of protein or peptide compositions
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.
WO2000076528A3 (en) Pharmaceutical preparation containing proteins
AU9747698A (en) Isolated and recombinant antimicrobial peptides thrombocidin-1 (tc-1) and thrombocidin-2 (tc-2) or variants thereof
AU2420997A (en) Oligopeptides for drug delivery
IL133076A (en) Solubilized sertraline pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 549729

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 73286/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998920426

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 501270

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998920426

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09424292

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 73286/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998920426

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载